

Fedratinib: A Review of Its Pharmacology and Clinical Use

ABSTRACT

Fedratinib (INREBIC®) is a JAK2-selective inhibitor that has been developed as an oral treatment for myelofibrosis. It was approved for the first time in the United States in August 2019 to treat adult patients with intermediate-2 or high-risk primary or secondary (post-polycythaemia vera or post-essential thrombocythemia) myelofibrosis. Fedratinib is an anilino-pyrimidine derivative and is metabolized by CYP3A4, CYP2C19 and flavin-containing monooxygenase-3. Fedratinib is mainly excreted in faeces, and the effective half-life is 41 hours. The recommended dosage is 400 mg once daily (with or without food). The dosage should be reduced to 200 mg once daily in patients receiving CYP3A4 inhibitors and in patients with severe renal impairment. Fedratinib's recent approval adds to the few therapeutic option choices available to individuals with MF. The most common adverse events were mild gastrointestinal toxicities. Fedratinib comes with a boxed warning about the risk of serious and potentially deadly encephalopathies, such as Wernicke's.

INTRODUCTION

Fedratinib is an oral kinase inhibitor that inhibits JAK2 and FMS-like tyrosine kinase 3 in both wild type and mutationally activated forms (FLT3). The US Food and Drug Administration (FDA) approved it for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-PV or post-ET) MF in August 2019.¹ Fedratinib (SAR302503/TG101348) is a JAK2-selective inhibitor that has shown therapeutic effect in MF patients in early-phase studies. It appears to have activity against a broader family of kinases and kinase mutants.^{2,3} Fedratinib has a modest inhibitory effect on JAK1, JAK3 and

tyrosine kinase 2 (TYK2).⁴ JAK1, JAK2, JAK3, and TYK2 are members of the Janus kinase (JAK) family of protein-tyrosine kinases.⁵ Fedratinib is an inhibitor of several cytochrome P450 (CYP)enzymes and is a weak inhibitor of CYP2D6 and a moderate inhibitor of CYP2C19, CYP3A4.⁶ Fedratinib binds to both the ATP-binding site and the substrate-binding site.⁷ Fedratinib was recently included to the National Comprehensive Care Network's MPN treatment guidelines as an initial therapy option for patients with intermediate-2 or high-risk MF or as second-line therapy for those who do not react to ruxolitinib or lose their response.⁸ In patients with MF, the highest tolerable dose of fedratinib was established to be 680 mg once daily (QD), and single oral doses of up to 680 mg fedratinib were tolerated by the healthy subjects. Fedratinib solubility is pH dependant; it is easily soluble at pH 1, but almost insoluble at pH 7.4 (112, 30, 0.02 and 0.004 mg/mL at pH 1, 4.5, 6.8, and 7.4, correspondingly).⁹


Table 1.

DEVELOPMENT OF FEDRATINIB	2005	JAK2V617F mutation discovered
	2006	First synthesis of TG101348(fedratinib)
	2006-2008	Preclinical studies
	2008	Human phase 1 trial open
	2011	JAKARTA trial
	2012	JAKARTA 2 trial
	2013-2017	FDA clinical hold
	2019	FREEDOM, FREEDOM 2 trials
	2019	FDA approval in myelofibrosis

CHEMICAL STRUCTURE AND DEVELOPMENT OF FEDRATINIB

In 2005, the JAK2V617F mutation was discovered, ushering in a new age of rationally planned targeted therapy for MPNs.¹⁰⁻¹³ The JAK2V617F mutation, which promotes JAK2 signalling, is the most prevalent somatic mutation in MPNs, and it is disease-causing and central to the pathogenesis of MPN.¹⁴⁻¹⁵ The therapeutic potential of an oncogenic kinase allele was immediately apparent, and JAK2 inhibitors were produced quickly and put to the test in the clinic. In the year 2011, The FDA authorised ruxolitinib as the first JAK2 inhibitor for treatment of MF, followed by fedratinib approval in 2019.¹⁶ The clinical activity of fedratinib in MF at the recommended beginning dose of 400 mg/day has been evaluated in JAK-inhibitor-naïve patients as well as individuals who have previously been treated with other JAK inhibitors (ruxolitinib).^{17,18} Fedratinib was discovered after a new series of pyrimidine-based inhibitors designed and optimised utilising rational structure-based approaches to target JAK2.^{19,20} Fedratinib is an anilino-pyrimidine derivative.²¹

STRUCTURE



IUPAC Name: N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl) ethoxy] phenyl} amino) pyrimidin-4-yl] amino} benzene-1-sulfonamide

Chemical Formula: C₂₇H₃₆N₆O₃S

PHARMACOLOGY

Fedratinib has a quick oral absorption rate, a high protein binding rate (>92 percent bound to protein), a long terminal half-life, and is primarily excreted through the faeces.²² Mostly processed by Cytochrome (CY)P3A4 in humans; hence, if fedratinib is given concurrently with powerful CYP3A4 inhibitors, its plasma levels may rise. Clarithromycin, voriconazole, itraconazole, and grapefruit juice are examples of potential culprit agents and both patients and community physicians should be aware of these potential interactions. If these agents cannot be avoided, dose reduction should be considered to reduce the risk of adverse effects. If the CYP3A4 inhibitor is stopped, dosage should be increased immediately.²³

JAK2 selectivity

Fedratinib was designed as a JAK2-selective inhibitor with better potency for JAK2 than closely related kinase family members utilising structure-based drug design. It binds to both the ATP and peptide-substrate binding sites in the kinase domain, according to structural modelling, which could explain why there is no hereditary resistance to fedratinib.²⁴

FLT3 inhibition

Fedratinib inhibits mutant and wild-type FLT3, a tyrosine kinase found in hematopoietic stem cells and myeloid progenitor cells that play a crucial function in cell survival as well as proliferation. FLT3 activation leads to phosphorylation and activation of the PI3K/AKT, MAPK, and STAT5 signalling pathways, which are involved in mechanisms of anti-apoptosis, proliferation, and differentiation pathways.^{25,26}

BRD4 inhibition

Fedratinib inhibits BRD4; fedratinib's dual targeting of JAK2 and bromodomains may contribute to the drug's therapeutic effect. Members of the group family of BET proteins (BRD2, BRD3, BRD4, and BRDT) are linked to a variety of malignancies.²⁷⁻³⁰

PHARMACOKINETICS

The pharmacokinetics and acceptability of single fedratinib dosages ranging from 10 to 680 mg were evaluated in a randomised, placebo-controlled phase I study in healthy volunteers. Drug was quickly absorbed, with peak plasma concentrations occurring 2–3 hours after dosing. Fedratinib exposure appeared to grow faster than dosage proportionality would predict, with a threefold increase in exposure in the 80–500 mg dose range compared to dosage proportionality. Similarly, mean steady-state maximum plasma concentration (C_{max}) and area under the concentration-time curve (AUC_{0-t}) values increased 54- and 88-fold, respectively, in patients with MF receiving fedratinib dosages of 30–800 mg/day.³¹ Fedratinib has a 41-hour effective half-life. By the 15th day of treatment, steady-state plasma concentrations had been attained. Fedratinib is metabolised by cytochrome P450 enzymes (CYP3A4, CYP2C19). Co-administration with CYP3A4 inhibitors (e.g., ketoconazole) can enhance fedratinib exposure (possible drug-drug interactions should be investigated prior to starting treatment).

In healthy volunteers, coadministration of a single dosage of 500 mg with pantoprazole (40 mg once daily) had no effect on fedratinib pharmacokinetics.³² Fedratinib accounts for around 80% of the circulating drug in plasma after oral administration, with 77 percent of the administered dose (23 percent unaltered) excreted in faeces and 5% (3 percent unchanged) excreted in urine following a single oral dose. With fedratinib, there was no clinically significant influence of age, race, sex, body weight. Fedratinib's pharmacokinetics are unaffected by mild to severe hepatic impairment or minor renal impairment. Moderate (creatinine clearance, 30-59 mL/min) or severe (creatinine clearance, 15-29 mL/min) renal impairment, on the other hand, resulted in increased fedratinib exposure. Dose reductions are required for severe renal impairment.³³ In two Phase I studies in healthy male subjects, the effect of food intake on the pharmacokinetics (PKs) and tolerability of single-dose fedratinib (FED12258: 100 mg or 500 mg) under fasted or fed [high fat breakfast] conditions; ALI13451: 500 mg under fasted or fed [low or high fat breakfast] conditions was investigated. The area under the plasma concentration—time curve extended to infinity for the 500 mg dosage was 0.96 (100 mg; high fat/fasted), 1.19–1.24 (500 mg; high fat/fasted), and 1.22 (500 mg; low fat/fasted). Fedratinib 500 mg reached maximal plasma concentration 4 hours after a high fat breakfast and 2–2.5 hours after a low-fat breakfast or when fasting; the terminal half-life was 76–88 hours (fasted) and 73–78 hours (nonfasted) (fed). Food consumption had minimal effect on fedratinib PKs, and the drug's tolerance was enhanced when given after a high-fat breakfast.³⁴

Table 2.

<p>Absorption</p>	<p>Peak plasma time: ~3 hr (steady-state)</p> <p>Peak plasma concentration: 1,804 ng/mL</p>
--------------------------	---

	<p>AUC: 26,870 ng·hr/mL</p> <p>Steady-state reached within 15 days</p> <p>Effect of food</p> <ul style="list-style-type: none"> • A low-fat, low-calorie or a high-fat, high-calorie meal increased AUC up to 24% and peak plasma concentration up to 14% of a single 500-mg dose
Distribution	<p>Vd (steady-state): 1,770 L</p> <p>Protein bound: ≥92%</p>
Metabolism	<p>Primarily metabolized by CYP3A4, CYP2C19, and flavin-containing monooxygenase 3 (FMO3)</p> <p>Fedratinib accounts for ~80% of total circulating drug in plasma after oral administration</p>
Elimination	<p>Half-life: ~ 114 hr</p> <p>Clearance: 13 L/hr</p> <p>Excretion: Faeces (77% [23% unchanged]); urine (5% [3% unchanged])</p>

PHARMACODYNAMICS

JAK/STAT signaling

Fedratinib lowered phosphorylation of downstream STAT3/5 proteins (pSTAT3/pSTAT5), slowed cell proliferation, and triggered apoptotic cell death in cell models expressing

mutationally active JAK2 or FLT3-ITD. Fedratinib, which inhibits pSTAT5, improved illness-associated characteristics in mice models of JAK2V617F-driven myeloproliferative illness, including reduced white blood cell (WBC) counts, haematocrit, splenomegaly, and reticulin fibrosis.³⁵ Fedratinib effectively suppressed KITD816V and FIP1L1-PDGFRΑ in leukemic cell lines, suggesting that the drug may have a function in the treatment of patients with chronic eosinophilic leukaemia.³⁶ Fedratinib inhibited JAK2/STAT1 signalling, which reduced monosomy 7 myelodysplastic syndrome (MDS) blasts in bone marrow cells suggesting it could be a targeted therapy for monosomy 7 MDS and acute myeloid leukaemia patients.³⁷

JAK2V617F

Fedratinib has been shown to be effective against JAK2V617F-expressing cells in animal studies.³⁸⁻⁴⁰ Fedratinib suppressed phosphorylation of STAT3/5, reduced splenomegaly, and improved white blood cell counts in mice with JAK2V617F-positive myeloproliferative illness, attenuated myelofibrosis, cell counts and haematocrit, and greater chances of surviving. It reduced cell proliferation and extended survival in a variety of solid tumour models. Concentrations of fedratinib less than 1 mol/L were shown to completely block colony formation in most tumour cell lines.⁴¹ Fedratinib's impact on JAK2V617F allele burden in MF patients is less known.⁴²

CLINICAL TRIALS OF FEDRATINIB

Phase I

MF-TG101348-001

NCT00631462

A phase 1, open label, dose escalation study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered FDR in patients with MF.

Objective to evaluate the safety and tolerability of the drug in patients with MF.

Phase II

JAKARTA2

NCT01523171

Adult patients with a current diagnosis of intermediate or high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythemia, myelofibrosis who were ruxolitinib resistant or intolerant after a minimum of 14 days of therapy were enrolled in this single-arm, open-label, non-randomised, phase 2 multicentre study, which was conducted at 31 sites in nine countries. Palpable splenomegaly (5 cm below the left costal margin), an Eastern Cooperative Oncology Group performance status of 2 or less, and a life expectancy of 6 months or fewer were the other key inclusion criteria. The primary goal of this phase 2 research was fulfilled, demonstrating that patients with ruxolitinib-resistant or ruxolitinib-intolerant myelofibrosis might benefit from fedratinib, though at the cost of some possible harm, which has to be investigated further. In the JAKARTA2 trial, there was one instance of grade 3 hepatic encephalopathy, but no verified case of Wernicke's encephalopathy (WE).

Phase III

JAKARTA

NCT01437787

Multicentre, randomized, double-blind, placebo-controlled, 3-arm study of FDR (400 or 500 mg or placebo) in patients with intermediate-2 or high-risk MF. Primary objective: to evaluate the efficacy of daily oral doses of 400 or 500 mg of the drug compared with placebo in the reduction of spleen volume. Secondary objectives: to evaluate the effect on MF-associated, the OS, PFS, durability of spleen response and drug safety. In the United States, regulatory approval of the recommended fedratinib 400 mg daily dosage for the treatment of individuals with intermediate-2 or high-risk MF was based in part on clinical effectiveness and safety in JAKARTA trial.

Phase III

FREEDOM

NCT03755518

(Resistant/intolerant to RUX)

Single-arm, open-label efficacy and safety trial of FDR in subjects with INT or high-risk MF previously treated with RUX. Primary objective to assess subjects gaining $\geq 35\%$ SVR and a key secondary objective is to evaluate the safety of FDR.

Phase III

FREEDOM2

NCT03952039

Single-arm, open-label efficacy and safety trial of FDR in subjects with INT or high-risk MF previously treated with RUX. The goal is to compare FDR with BAT in terms of efficacy and

safety. The primary goal is to determine the percentage of participants in the FDR and BAT arms who have an SVR of at least 35 percent.

SAFETY

Fedratinib's safety and tolerability were assessed using the treatment-emergent adverse events (TEAEs). Between the first dosage of fedratinib and 30 days following the final dosage, a TEAE was defined as any AE that emerged, worsened, or became severe.⁴³ In clinical studies eight out of 877 individuals had cases consistent with Wernicke's encephalopathy. As a result, the US Food and Drug Administration (FDA) placed a clinical hold on the development of fedratinib. While the probable cases of Wernicke's encephalopathy (a neurological side effect brought upon by thiamine deficiency) were being investigated in 2013. In August 2017, the US FDA lifted the clinical hold after receiving further safety data.^{44,45,46} Fedratinib comes with a boxed warning about the risk of serious and potentially deadly encephalopathies, such as Wernicke's.⁴⁷

The following clinically significant side effects are listed elsewhere in the labelling of fedratinib

- Encephalopathy, including Wernicke's
Wernicke's encephalopathy is a neurologic emergency resulting from thiamine (Vitamin B1) deficiency. Signs and symptoms of Wernicke's encephalopathy may include ataxia, mental status changes, and ophthalmoplegia (e.g., nystagmus, diplopia)
- Anemia and Thrombocytopenia
- Gastrointestinal Toxicity
- Hepatic Toxicity
- Amylase and Lipase Elevation

CONCLUSION

Fedratinib is an exciting new treatment option for patients with advanced MF who previously had few therapeutic alternatives. Fedratinib has a longer track record in clinical trials. The possibility of secondary resistance developing during therapy must be determined. Fedratinib therapy significantly reduced symptoms in patients with MF but these benefits were accompanied by toxic effects in some patients, the most important being encephalopathy of unknown mechanism.

COMPETING INTERESTS DISCLAIMER:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

REFERENCES

1. Dioverti MV, Abu Saleh OM, Tande AJ. Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature. *Infect Dis (Lond)*. 2018;50(5):381-387.
2. Talpaz M, Jamieson C, Gabrail N, et al. Modulation of plasma cytokines and its association with clinical response to treatment with the JAK2-selective inhibitor SAR302503 in myelofibrosis (MF). *J Clin Oncol*. 2013;31(suppl15): abstr 7110.
3. Gotlib J, Pardanani A, Jamieson C, et al. Long-term follow up of a phase 1/2 study of SAR302503, an oral JAK2 selective inhibitor, in patients with myelofibrosis (MF). *Haematologica*.2012;97(s1):145.

4. Zhou T, Georgeon S, Moser R, et al. Specificity and mechanism of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348). *Leukemia*. 2014;28(2):404–7.
5. Williams NK, Bamert RS, Patel O, Wang C, Walden PM, Wilks AF, et al. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. *J Mol Biol* 2009; 387:219–32.
6. Ogasawara K, LoRusso PM, Olszanski AJ, Rixe O, Xu C, Yin J, Palmisano M, Krishna G. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. *Cancer Chemotherapy and Pharmacology*. 2020 Jul;86(1):87-95.
7. Ragheb M, Harrison CN, McLornan DP. Current and future role of fedratinib in the treatment of myelofibrosis. *Future Oncology*. 2020 Feb;16(6):175-86.
8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology –Myeloproliferative Neoplasms Version3.2019.2019. <https://www.nccn.org/patients/guidelines/content/PDF/mpnpatient.pdf>. Accessed August 23, 2019.
9. U.S. Food and Drug Administration (2019) U.S. Food and Drug Administration. Drug approval package: INREBIC—product quality review(s). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000ChemR.pdf. Accessed 26 Mar2020.
10. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell*. 2005;7(4):387-397.
11. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. *N Engl J Med*. 2005;352(17):1779-1790.

12. James C, Ugo V, Le Cou' edic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature*. 2005;434(7037):1144-1148.
13. Baxter EJ, Scott LM, Campbell PJ, et al; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet*. 2005;365(9464):1054-1061
14. Chen E, Mullally A. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms? *Hematology Am Soc Hematol EducProgram*. 2014; 2014:268-276.
15. Mead AJ, Mullally A. Myeloproliferative neoplasm stem cells. *Blood*. 2017;129(12):1607-1616.
16. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. *N Engl J Med*. 2015;372(5):426-435.
17. Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. *JAMA Oncol*. 2015; 1:643–51.
18. Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. *Lancet Haematol*. 2017;4: e317–24.
19. Boggon TJ, Li Y, Manley PW, Eck MJ. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. *Blood*. 2005;106(3):996-1002.
20. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. *Nat Rev Immunol*. 2006;6(8):595-601.

21. Roskoski Jr R. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. *Pharmacological research*. 2016 Sep 1; 111:784-803.
22. Ragheb M, Harrison CN, McLornan DP. Current and future role of fedratinib in the treatment of myelofibrosis. *Future Oncology*. 2020 Feb;16(6):175-86.
23. Ragheb M, Harrison CN, McLornan DP. Current and future role of fedratinib in the treatment of myelofibrosis. *Future Oncology*. 2020 Feb;16(6):175-86.
24. Kesarwani M, Huber E, Kincaid Z, Evelyn CR, Biesiada J, Rance M, et al. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. *Sci Rep*. 2015; 5:14538.
25. Kiyoi H. Flt3 inhibitors: Recent advances and problems for clinical application. *Nagoya J Med Sci*. 2015; 77:7–17.
26. Small D. FLT3 mutations: biology and treatment. *Hematol AmSoc Hematol Educ Program*. 2006; 1:178–84.
27. Ciceri P, Muller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. *Nat Chem Biol*. 2014; 10:305–12
28. Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, et al. Dual targeting of oncogenic activation and inflammatory signalling increases therapeutic efficacy in myeloproliferative neoplasms. *Cancer Cell*. 2018; 33:29–43 e7.
29. Muller S, Filippakopoulos P, Knapp S. Bromodomains as therapeutic targets. *Expert Rev Mol Med*. 2011;13: e29.
30. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, et al. Suppression of inflammation by a synthetic histone mimic. *Nature*. 2010; 468:1119–23.

31. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. *J Clin Oncol.* 2011; 29:789–96.
32. Xu C, Shamiyeh E, Kanamaluru V, Von Moltke L, Vince B, Zhang M. A Gastric pH modifier pantoprazole did not significantly affect the on pharmacokinetics of fedratinib in healthy male subjects: PI-085. *Clinical Pharmacology & Therapeutics.* 2015 Feb;97.
33. Blair HA. Fedratinib: first approval. *Drugs.* 2019;79(15):1719-1725.
34. Zhang M, Xu C, Ma L, Shamiyeh E, Yin J, von Moltke LL, Smith WB. Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteers. *Clinical pharmacology in drug development.* 2015 Jul;4(4):315-21.
35. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. *Cancer Cell.* 2008; 13:311–20.
36. Kittur J, Lasho TL, Butterfield JH, et al. TG101348, an orally bioavailable JAK2-selective inhibitor, potently inhibits KITD816V and FIP1L1-PDGFR α in vitro [abstract no. 2807]. *Blood.* 2008;112(11):2807.
37. Olnes MJ, Poon A, Tucker Z, Young NS, Sloan EM. JAK2 inhibition with TG101348 inhibits monosomy 7 myelodysplastic syndromes (MDS) bone marrow cells in vitro: a potential targeted therapy for monosomy 7 MDS. *Blood.* 2010 Nov 19;116(21):973.
38. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. *Cancer Cell.* 2008; 13:311–20.

39. Lasho TL, Tefferi A, Hood JD, Verstovsek S, Gilliland DG, Pardanani A. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. *Leukemia*. 2008; 22:1790–2.
40. Geron I, Abrahamsson AE, Barroga CF, Kavalerchik E, Gotlib J, Hood JD, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. *Cancer Cell*. 2008;13:321–30.
41. Greco R, Hurley R, Sun F, Yang L, Yu Q, Williams J, Dorsch M, Cohen P, Adrián F. SAR302503: A Jak2 inhibitor with antitumor activity in solid tumor models.
42. Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. *American journal of hematology*. 2020 Jun;95(6):594-603.
43. Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. *American journal of hematology*. 2020 Jun;95(6):594-603.
44. Day GS, del Campo CM. Wernicke encephalopathy: a medical emergency. *CMAJ*. 2014;186(8): E295.
45. Harrison C, Schaap N, Vannucchi A, Kiladjian JJ, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Gerike T, Rose S, Zhang J. Fedratinib induces spleen responses and

reduces symptom burden as first-line or salvage therapy in patients with myeloproliferative neoplasm-associated intermediate-or high-risk myelofibrosis (MF) and low platelet counts. *Clinical Lymphoma, Myeloma and Leukemia*. 2019 Sep 1;19: S355.

46. Zhang Q, Zhang Y, Diamond S, Boer J, Harris JJ, Li Y, Rupar M, Behshad E, Gardiner C, Collier P, Liu P. The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy. *Drug Metabolism and Disposition*. 2014 Oct 1;42(10):1656-62.
47. Celgene Corporation. INREBIC ® (fedratinib) capsules, for oral use: US prescribing information. 2019. <http://www.fda.gov/>. Accessed 16 Aug 2019.